Skip to main content

Table 2 Association between montelukast use and risk of different out-comes (significantly protective hazard ratios in bold)a

From: Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified

Study group Cases/Total (%) Hazard ratios (95% CI)
Montelukast pos Montelukast neg Ageb Unadjusted Adjusted
Dementia medicinec 489/23,521 (2.1) 4967/178,884 (2.9) >60 0.94 (0.85–1.03) 0.89 (0.81–0.98)
Nursing homed 507/23,634 (2.2) 5459/179,768 (3.1) 60–75 0.65 (0.57–0.74) 0.67 (0.59–0.77)
>75 1.00 (0.88–1.13) 0.99 (0.87–1.13)
Deathd 5512/23,634 (30.4) 55,857/179,768 (45.1) 60–75 0.86 (0.82–0.89) 0.64 (0.61–0.67)
>75 0.95 (0.92–0.98) 0.81 (0.78–0.84)
Parkinson’s medicinee 691/23,371 (3.0) 4550/178,134 (2.6) >60 1.21 (1.12–1.32) 1.06 (0.98–1.15)
Diabetes medicinee 1523/22,270 (7.3) 11,247/170,157 (7.1) >60 1.01 (0.96–1.07) 0.85 (0.80–0.90)
  1. aThe hazard ratios are based on comparing subjects using montelukast with those using only inhaling corticosteroids. The adjusted ratios are adjusted for sex, receiving drugs for heart conditions, and having a high consumption of drugs during the follow up period. The discrepancies between the sum of users in each analysis, and the grand total of 203,473 in Table 1, are due to truncations. The total number of person-years follow-up was between 1,346,308 and 1,480,476 (average 7.0–7.3 years per subject)
  2. bAs of 2014
  3. cThe adjusted analysis was stratified on having a high consumption of drugs dispensed per day, because this covariate did not meet the proportional hazards assumption
  4. dAs the effect of montelukast did not meet the proportional hazards assumption, the model was fitted by splitting into two age-periods, 60–75 years and >75 years
  5. eThe adjusted analysis was stratified on having a high consumption of drugs dispensed per day, and prescription of cardiovascular medicine, because these covariates did not meet the proportional hazards assumption